Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN2312 in Relapsed or Refractory Acute Myeloid Leukemia
NCT07873827Phase 2Not yet recruiting
- Sponsor
- Stemline Therapeutics
- Start
- Oct 2026
- Primary completion
- May 2028
01
Overview
A Phase 2 trial of MEN2312 in acute myeloid leukemia (AML), sponsored by Stemline Therapeutics. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
MEN2312
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07873827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07873827.